Johnson & Johnson (JNJ) Gross Margin (2009 - 2026)
Johnson & Johnson (JNJ) posted Gross Margin of 68.19% for Q2 2026, up 2.83% sequentially from 66.31% in Q1 2026, and up 32.0% YoY from 51.66% in Q2 2025.
Johnson & Johnson (JNJ) Gross Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Gross Margin for 18 years, with the latest figure at 68.19% in Q2 2026.
- Quarterly Gross Margin rose 32.0% year-over-year to 68.19% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 67.91% (down 1.0% YoY) and the FY2025 annual result came in at 67.88%, down 119.0% from the prior year.
- Gross Margin advanced to 68.19% in Q2 2026 per JNJ's latest filing, from 66.31% in the prior quarter.
- Over five years, Gross Margin peaked at 69.97% in Q3 2023 and troughed at 66.31% in Q1 2026.
- A 5-year average of 68.58% and a median of 68.87% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin surged 155 bps in 2024, then slumped 315 bps in 2025.
- Over 5 years, Gross Margin stood at 69.13% in 2022, then retreated by 1 bps to 68.23% in 2023, then climbed by 0 bps to 68.35% in 2024, then declined by 1 bps to 67.56% in 2025, then gained by 1 bps to 68.19% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 68.19%, 66.31%, and 67.56% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 78.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 83.60% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 72.04% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 79.76% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 72.78% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 73.05% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 68.19% |
| Mar 29, 2026 | 66.31% |
| Dec 28, 2025 | 67.56% |
| Sep 28, 2025 | 69.56% |
| Jun 29, 2025 | 67.87% |
| Mar 30, 2025 | 66.40% |
| Dec 29, 2024 | 68.35% |
| Sep 29, 2024 | 69.01% |
| Jun 30, 2024 | 69.40% |
| Mar 31, 2024 | 69.55% |
| Dec 31, 2023 | 68.23% |
| Oct 1, 2023 | 69.06% |
| Jul 2, 2023 | 69.97% |
| Apr 2, 2023 | 68.00% |
| Jan 1, 2023 | 69.49% |
| Oct 2, 2022 | 69.13% |
| Jul 3, 2022 | 68.73% |
| Apr 3, 2022 | 69.67% |
| Oct 3, 2021 | 68.93% |
| Jul 4, 2021 | 67.45% |